Your browser doesn't support javascript.
loading
IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity.
Chiang, Sarah; Weigelt, Britta; Wen, Huei-Chi; Pareja, Fresia; Raghavendra, Ashwini; Martelotto, Luciano G; Burke, Kathleen A; Basili, Thais; Li, Anqi; Geyer, Felipe C; Piscuoglio, Salvatore; Ng, Charlotte K Y; Jungbluth, Achim A; Balss, Jörg; Pusch, Stefan; Baker, Gabrielle M; Cole, Kimberly S; von Deimling, Andreas; Batten, Julie M; Marotti, Jonathan D; Soh, Hwei-Choo; McCalip, Benjamin L; Serrano, Jonathan; Lim, Raymond S; Siziopikou, Kalliopi P; Lu, Song; Liu, Xiaolong; Hammour, Tarek; Brogi, Edi; Snuderl, Matija; Iafrate, A John; Reis-Filho, Jorge S; Schnitt, Stuart J.
Afiliación
  • Chiang S; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. chiangs@mskcc.org sschnitt@bidmc.harvard.edu.
  • Weigelt B; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Wen HC; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Pareja F; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Raghavendra A; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Martelotto LG; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Burke KA; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Basili T; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Li A; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Geyer FC; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Piscuoglio S; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Ng CK; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Jungbluth AA; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Balss J; German Consortium of Translational Cancer Research (DKTK), Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Pusch S; German Consortium of Translational Cancer Research (DKTK), Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Baker GM; Department of Pathology, University of Chicago, Chicago, Illinois.
  • Cole KS; Department of Pathology, University of Iowa Hospital and Clinics, Iowa City, Iowa.
  • von Deimling A; German Consortium of Translational Cancer Research (DKTK), Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Batten JM; Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany.
  • Marotti JD; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
  • Soh HC; Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
  • McCalip BL; Pathology North, North Shore Private Hospital, New South Wales, Australia.
  • Serrano J; Miami Valley Hospital, Dayton, Ohio.
  • Lim RS; Department of Pathology, New York University Langone Medical Center and Medical School, New York, New York.
  • Siziopikou KP; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Lu S; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Liu X; Department of Pathology, Mon General Hospital, Morgantown, West Virginia.
  • Hammour T; ABQ Health Partners, Albuquerque, New Mexico.
  • Brogi E; Maine Medical Center, Portland, Maine.
  • Snuderl M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Iafrate AJ; Department of Pathology, New York University Langone Medical Center and Medical School, New York, New York.
  • Reis-Filho JS; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
  • Schnitt SJ; Department of Pathology, Harvard Medical School, Boston, Massachusetts.
Cancer Res ; 76(24): 7118-7129, 2016 12 15.
Article en En | MEDLINE | ID: mdl-27913435
ABSTRACT
Solid papillary carcinoma with reverse polarity (SPCRP) is a rare breast cancer subtype with an obscure etiology. In this study, we sought to describe its unique histopathologic features and to identify the genetic alterations that underpin SPCRP using massively parallel whole-exome and targeted sequencing. The morphologic and immunohistochemical features of SPCRP support the invasive nature of this subtype. Ten of 13 (77%) SPCRPs harbored hotspot mutations at R172 of the isocitrate dehydrogenase IDH2, of which 8 of 10 displayed concurrent pathogenic mutations affecting PIK3CA or PIK3R1 One of the IDH2 wild-type SPCRPs harbored a TET2 Q548* truncating mutation coupled with a PIK3CA H1047R hotspot mutation. Functional studies demonstrated that IDH2 and PIK3CA hotspot mutations are likely drivers of SPCRP, resulting in its reversed nuclear polarization phenotype. Our results offer a molecular definition of SPCRP as a distinct breast cancer subtype. Concurrent IDH2 and PIK3CA mutations may help diagnose SPCRP and possibly direct effective treatment. Cancer Res; 76(24); 7118-29. ©2016 AACR.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Carcinoma Papilar / Fosfatidilinositol 3-Quinasas / Isocitrato Deshidrogenasa Límite: Female / Humans Idioma: En Revista: Cancer Res Año: 2016 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Carcinoma Papilar / Fosfatidilinositol 3-Quinasas / Isocitrato Deshidrogenasa Límite: Female / Humans Idioma: En Revista: Cancer Res Año: 2016 Tipo del documento: Article
...